[1]University Health Network University of Toronto, Princess Margaret Cancer Centre,Toronto,Canada
[2]American University of Beirut, Departments of Biochemistry and Molecular Genetics,Beirut,Lebanon
[3]Princess Margaret Cancer Centre,Toronto,Canada
[4]University of Toronto, Department of Computer Science,Toronto,Canada
[5]Danmarks Tekniske Universitet,Lyngby,Denmark
[6]Weill Cornell Medical College, Department of Physiology and Biophysics,New York,United States
[7]Yale University School of Medicine,New Haven,United States
[8]Fudan University, School of Life Sciences,Shanghai,China
[9]s Hospital, Department of Radiation Oncology,Boston,United States
[10]Dana-Farber Cancer Institute, Department of Biostatistics and Computational Biology,Boston,United States
In 2013 we published an analysis demonstrating that drug response data and gene-drug associations reported in two independent large-scale pharmacogenomic screens, Genomics of Drug Sensitivity in Cancer (GDSC) and Cancer Cell Line Encyclopedia (CCLE), were inconsistent. The GDSC and CCLE investigators recently reported that their respective studies exhibit reasonable agreement and yield similar molecular predictors of drug response, seemingly contradicting our previous findings. Reanalyzing the authors' published methods and results, we found that their analysis failed to account for variability in the genomic data and more importantly compared different drug sensitivity measures from each study, which substantially deviate from our more stringent consistency assessment. Our comparison of the most updated genomic and pharmacological data from the GDSC and CCLE confirms our published findings that the measures of drug response reported by these two groups are not consistent. We believe that a principled approach to assess the reproducibility of drug sensitivity predictors is necessary before envisioning their translation into clinical settings. © 2016 Safikhani Z et al.
(8.0+极速模式)